Catalent’s Cell & Gene Therapy track record speaks for itself. We have worked with more than 20 premier cell and gene therapy innovators. We have experience with more than 275+ autologous batches, 1000+ allogeneic batch vials, and 60+ gene therapy programs. Catalent also has programs underway to scale-up the potentially first allogeneic CAR-T therapy. Our combined scale-up power across plasmid DNA , viral vector production, and cell therapy manufacturing strongly positions Catalent as the full-service manufacturing partner for autologous and allogeneic therapies globally.
At Catalent, we operate with a patient first vision. Your success is our success and we believe in creating a strong partnership together with our clients to deliver on our shared vision of saving lives each day with innovative treatments.